Updates on Annamycin and WP1066
VANCOUVER, British Columbia, July 06, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc.
On June 25, Moleculin announced its presentation at the American Association of Cancer Research (AACR) Annual Meeting
........overview of data demonstrating that uniquely high uptake and retention of Annamycin in the lungs results in consistently high in vivo activity against wide range of lung-localized tumors in mice.
https://ir.moleculin.com/press-releases/detail/180/moleculin-announces-preclinical-data-confirms-efficacy-of Annamycin in Lung Metastases
On July 1, 2020, Moleculin announced that a peer-reviewed article published in Clinical Cancer Research (Clin Cancer Res June 30 2020 DOI:10.1158/1078-0432.CCR-19-4092) reported findings that Moleculin's STAT3 inhibitor, WP1066, used in combination with traditional whole brain radiation therapy resulted in long-term survivors and enhanced median survival time relative to monotherapy in mice with implanted human brain tumors.
The study was performed by lead author Martina Ott, Ph.D., Instructor of Neurosurgery, senior author Amy Heimberger, M.D., professor of Neurosurgery, and a team of researchers at The University of Texas MD Anderson Cancer Center.
On July 2, 2020, Moleculin announced that it has received approval to increase the increment for Annamycin dose-escalation from 30 mg/m2 per cohort to 60 mg/m2 per cohort in studies conducted in the European Union, as treatment to date in its clinical trials has been at what Moleculin considers to be sub-therapeutic levels.
The first patient in the current cohort was treated at 240 mg/m2 with no evidence of cardiotoxicity or other dose limiting toxicities.
Moleculin stated that once 2 more patients are successfully treated at this level, the next cohort will be treated with 300 mg/m2.
With these timing and dosing expectations, Moleculin stated it believes that European dosing will increase in 2020, allowing a recommended Phase 2 Dose to be established in 2021.
https://www.globenewswire.com/news-release/2020/07/06/2057855/0/en/WPD-Pharmaceuticals-Licensor-Announces-Updates-on-Annamycin-and-WP1066.html